Enanta Pharmaceuticals (ENTA) Return on Capital Employed (2013 - 2026)
Enanta Pharmaceuticals posted quarterly Return on Capital Employed of 21.91% for Q1 2026, up 1332.0% year-on-year from 1.53% in Q1 2025, and up 21.93% on a QoQ basis from 28.06% in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 14 years of Return on Capital Employed data on file, last reported at 21.91% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1332.0% year-over-year to 21.91%; the trailing twelve-month figure through Mar 2026 stood at 21.91% (up 1332.0% YoY), and the FY2025 full-year result was 30.47%, up 316.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.91%, up from 28.06% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 21.91% in Q1 2026 and bottomed at 42.34% in Q1 2023.
- The 5-year median for Return on Capital Employed is 35.31% (2024), against an average of 34.86%.
- The widest annual swing landed in 2022, when Return on Capital Employed plunged 1465 bps; it then soared 1332 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 36.47% in 2022, then fell by 2 bps to 37.1% in 2023, then advanced by 5 bps to 35.19% in 2024, then climbed by 20 bps to 28.06% in 2025, then climbed by 22 bps to 21.91% in 2026.
- The last three Return on Capital Employed figures came in at 21.91% (Q1 2026), 28.06% (Q4 2025), and 35.22% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -21.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.91% |
| Dec 31, 2025 | -28.06% |
| Sep 30, 2025 | -35.22% |
| Jun 30, 2025 | -36.20% |
| Mar 31, 2025 | -35.23% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -36.85% |
| Jun 30, 2024 | -35.31% |
| Mar 31, 2024 | -36.95% |
| Dec 31, 2023 | -37.10% |
| Sep 30, 2023 | -32.99% |
| Jun 30, 2023 | -38.88% |
| Mar 31, 2023 | -42.34% |
| Dec 31, 2022 | -36.47% |
| Sep 30, 2022 | -35.34% |
| Jun 30, 2022 | -34.99% |
| Mar 31, 2022 | -33.55% |
| Dec 31, 2021 | -31.78% |
| Sep 30, 2021 | -26.83% |
| Jun 30, 2021 | -22.21% |
| Mar 31, 2021 | -18.90% |
| Dec 31, 2020 | -14.51% |
| Sep 30, 2020 | -8.77% |
| Jun 30, 2020 | -3.16% |
| Mar 31, 2020 | 2.27% |
| Dec 31, 2019 | 4.52% |
| Sep 30, 2019 | 8.00% |
| Jun 30, 2019 | 14.49% |
| Mar 31, 2019 | 19.12% |
| Dec 31, 2018 | 24.74% |
| Sep 30, 2018 | 23.21% |
| Jun 30, 2018 | 30.66% |
| Mar 31, 2018 | 21.90% |
| Dec 31, 2017 | 14.64% |
| Sep 30, 2017 | 8.78% |
| Jun 30, 2017 | -12.31% |
| Mar 31, 2017 | -7.70% |
| Dec 31, 2016 | -4.32% |
| Sep 30, 2016 | 11.27% |
| Jun 30, 2016 | 13.82% |
| Mar 31, 2016 | 15.08% |
| Dec 31, 2015 | 35.62% |
| Sep 30, 2015 | 52.79% |
| Jun 30, 2015 | 49.10% |
| Mar 31, 2015 | 70.35% |
| Dec 31, 2014 | 57.17% |
| Sep 30, 2014 | 12.43% |
| Jun 30, 2014 | 15.12% |
| Mar 31, 2014 | -18.57% |
| Dec 31, 2013 | -16.52% |
| Sep 30, 2013 | 7.93% |
| Jun 30, 2013 | 8.05% |